Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
Background: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rawalpindi Medical University
2018-12-01
|
| Series: | Journal of Rawalpindi Medical College |
| Subjects: | |
| Online Access: | https://www.journalrmc.com/index.php/JRMC/article/view/991 |
| _version_ | 1818368640415694848 |
|---|---|
| author | Muhammad Ikhlaq Maryam Jalil Syed Dawar Muhammad Ashraf |
| author_facet | Muhammad Ikhlaq Maryam Jalil Syed Dawar Muhammad Ashraf |
| author_sort | Muhammad Ikhlaq |
| collection | DOAJ |
| description | Background: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.
Objectives: To compare the treatment response in treatment naive and treatment experienced chronic hepatitis C patients treated with sofosbuvir and ribavirin to determine the efficacy of this drug combination.
Methods: In this experimental study 104 chronic hepatitis C patients with positive polymerase chain reaction (PCR) for hepatitis C virus (HCV) and high alanine aminotransferase (ALT) levels were included. Out of them 66 (63.5%) were treatment naive (received treatment for the first time) and 38 (36.5%) were treatment experienced. Sofosbuvir 400mg once a day in combination with ribavirin was given for 6 months and treatment responses were noted at 4, 12 and 24 weeks. SPSS version 21 was used to analyze the data.
Results: The end treatment response in 104 chronic hepatitis C patients was calculated in which 99 (95.2%) patients responded to the therapy. 63 (95.5%) treatment naive patients and 36 (94.7%) treatment experienced responded to the therapy. End treatment response (ETR) in chronic hepatitis C patients to sofosbuvir and ribavirin was irrespective to their gender and genotypes and test of significance came out as insignificant (p > 0.05).
Conclusion: Sofosbuvir is effective for both treatment naive and treatment experienced chronic hepatitis C patients. This regimen is equally effective for both genders and all genotypes of hepatitis C.
Keywords: , , , , , . |
| first_indexed | 2024-12-13T23:11:10Z |
| format | Article |
| id | doaj.art-4172b0da21b4484584522f69a8647ed7 |
| institution | Directory Open Access Journal |
| issn | 1683-3562 1683-3570 |
| language | English |
| last_indexed | 2024-12-13T23:11:10Z |
| publishDate | 2018-12-01 |
| publisher | Rawalpindi Medical University |
| record_format | Article |
| series | Journal of Rawalpindi Medical College |
| spelling | doaj.art-4172b0da21b4484584522f69a8647ed72022-12-21T23:28:06ZengRawalpindi Medical UniversityJournal of Rawalpindi Medical College1683-35621683-35702018-12-0122S-1Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced PatientsMuhammad Ikhlaq0Maryam Jalil1Syed Dawar2Muhammad Ashraf3Final year M.B.B.S student Rawalpindi Medical College, RawalpindiWoman medical officer at THQ Hospital, Fateh JangWoman medical officer at THQ Hospital, Fateh JangHouse Officer, RMU Allied Hospitals, RawalpindiBackground: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance. Objectives: To compare the treatment response in treatment naive and treatment experienced chronic hepatitis C patients treated with sofosbuvir and ribavirin to determine the efficacy of this drug combination. Methods: In this experimental study 104 chronic hepatitis C patients with positive polymerase chain reaction (PCR) for hepatitis C virus (HCV) and high alanine aminotransferase (ALT) levels were included. Out of them 66 (63.5%) were treatment naive (received treatment for the first time) and 38 (36.5%) were treatment experienced. Sofosbuvir 400mg once a day in combination with ribavirin was given for 6 months and treatment responses were noted at 4, 12 and 24 weeks. SPSS version 21 was used to analyze the data. Results: The end treatment response in 104 chronic hepatitis C patients was calculated in which 99 (95.2%) patients responded to the therapy. 63 (95.5%) treatment naive patients and 36 (94.7%) treatment experienced responded to the therapy. End treatment response (ETR) in chronic hepatitis C patients to sofosbuvir and ribavirin was irrespective to their gender and genotypes and test of significance came out as insignificant (p > 0.05). Conclusion: Sofosbuvir is effective for both treatment naive and treatment experienced chronic hepatitis C patients. This regimen is equally effective for both genders and all genotypes of hepatitis C. Keywords: , , , , , .https://www.journalrmc.com/index.php/JRMC/article/view/991End treatment responseTreatment responseChronic hepatitis CSofosbuvirRibavirinGenotype |
| spellingShingle | Muhammad Ikhlaq Maryam Jalil Syed Dawar Muhammad Ashraf Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients Journal of Rawalpindi Medical College End treatment response Treatment response Chronic hepatitis C Sofosbuvir Ribavirin Genotype |
| title | Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients |
| title_full | Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients |
| title_fullStr | Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients |
| title_full_unstemmed | Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients |
| title_short | Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients |
| title_sort | treatment response to sofosbuvir and ribavirin in chronic hepatitis c patients and comparison of naive and treatment experienced patients |
| topic | End treatment response Treatment response Chronic hepatitis C Sofosbuvir Ribavirin Genotype |
| url | https://www.journalrmc.com/index.php/JRMC/article/view/991 |
| work_keys_str_mv | AT muhammadikhlaq treatmentresponsetosofosbuvirandribavirininchronichepatitiscpatientsandcomparisonofnaiveandtreatmentexperiencedpatients AT maryamjalil treatmentresponsetosofosbuvirandribavirininchronichepatitiscpatientsandcomparisonofnaiveandtreatmentexperiencedpatients AT syeddawar treatmentresponsetosofosbuvirandribavirininchronichepatitiscpatientsandcomparisonofnaiveandtreatmentexperiencedpatients AT muhammadashraf treatmentresponsetosofosbuvirandribavirininchronichepatitiscpatientsandcomparisonofnaiveandtreatmentexperiencedpatients |